ArticleEBioMedicine2025
Exploring the relationship between medications and heat-related community deaths during the 2021 heat dome: a hybrid approach using machine learning.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of potentially heat-vulnerability increasing drugs - a narrative review.European journal of clinical pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtreme heat events (EHEs) are a growing threat to health worldwide. To date, only a limited number of studies have evaluated medications as risk or protective factors for mortality during EHEs.
methodsWe explored the relationship between dispensed pharmaceuticals and heat-related community deaths using linked administrative health data and both logistic regression (LR) and machine learning (ML) models. We conducted a case-control study during the 2021 EHE in British Columbia, Canada, including 504 community deaths from heat exposure as cases and 2520 similar controls who survived the EHE. We used medications dispensed 30, 60 and 90 days prior to death (or 30, 60 and 90 days before the end of the EHE for controls) as predictors, grouped by Anatomical Therapeutic Chemical (ATC) classification at level 2 for LR (28 classes) and level 4 for ML (270 subclasses). Models were adjusted for multiple covariates, including common chronic diseases.
findingsResults from LR showed increased odds of mortality associated with dispensations of antiepileptics, anti-Parkinson drugs, psycholeptics, diuretics, drugs for diabetes, beta blocking agents, analgesics, urologicals and drugs for treatment of bone diseases. We observed a protective association with dispensations of calcium channel blockers and ophthalmologicals. Results varied by sex, age, and other covariates. The ML model highlighted the most computationally important subclasses of medications within each of the ATC level 2 classes.
interpretationThis study leveraged both LR and ML to generate insights about medications and mortality during EHEs. The results add to the existing evidence on pharmaceutical risks during EHEs and provide new avenues for further research. They can be used to help develop more targeted messages to inform individuals whose medications put them at greater risk during EHEs.
fundingBC Centre for Disease Control and Ministère de l'Enseignement supérieur du Québec.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.